Kamal Hamed

Kamal Hamed is the Chief Medical Officer at Spero Therapeutics. Kamal has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals. Before joining Spero, he was Chief Medical Officer at Lysovant Sciences, Inc., a subsidiary of Roivant Sciences, Inc. Preceding Lysovant, Kamal was Head of Clinical Development & Medical Affairs at Basilea Pharmaceutica International, and prior to Basilea, he had held senior positions in clinical development and medical affairs at Novartis Pharmaceuticals Corporation (including Therapeutic Area Head for Anti-infectives), Bristol-Myers Squibb, and Bayer Corporation, spearheading the successful global development, approval, and post-marketing medical affairs support of multiple anti-infectives.

Kamal holds an MD degree from the American University of Beirut, an MPH degree from the Johns Hopkins University, and an MBA degree from the University of South Florida. He completed a residency in Internal Medicine at UMDNJ–Robert Wood Johnson Medical School and a fellowship in Infectious Diseases at Stanford University School of Medicine. Kamal worked as an academic physician for 14 years before joining Pharma, is a fellow of both the American College of Physicians and the Infectious Diseases Society of America, and has published over 110 manuscripts in peer-reviewed journals.